Cargando…

Issues associated with the use of phosphospecific antibodies to localise active and inactive pools of GSK-3 in cells

ABSTRACT: BACKGROUND: Glycogen synthase kinase-3 (GSK-3) is a ubiquitously expressed serine/threonine (Ser/Thr) kinase comprising two isoforms, GSK-3α and GSK-3β. Both enzymes are similarly inactivated by serine phosphorylation (GSK-3α at Ser21 and GSK-3β at Ser9) and activated by tyrosine phosphory...

Descripción completa

Detalles Bibliográficos
Autores principales: Campa, Victor M, Kypta , Robert M
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3039639/
https://www.ncbi.nlm.nih.gov/pubmed/21261990
http://dx.doi.org/10.1186/1745-6150-6-4
_version_ 1782198213351047168
author Campa, Victor M
Kypta , Robert M
author_facet Campa, Victor M
Kypta , Robert M
author_sort Campa, Victor M
collection PubMed
description ABSTRACT: BACKGROUND: Glycogen synthase kinase-3 (GSK-3) is a ubiquitously expressed serine/threonine (Ser/Thr) kinase comprising two isoforms, GSK-3α and GSK-3β. Both enzymes are similarly inactivated by serine phosphorylation (GSK-3α at Ser21 and GSK-3β at Ser9) and activated by tyrosine phosphorylation (GSK-3α at Tyr279 and GSK-3β at Tyr216). Antibodies raised to phosphopeptides containing the sequences around these phosphorylation sites are frequently used to provide an indication of the activation state of GSK-3 in cell and tissue extracts. These antibodies have further been used to determine the subcellular localisation of active and inactive forms of GSK-3, and the results of those studies support roles for GSK-3 phosphorylation in diverse cellular processes. However, the specificity of these antibodies in immunocytochemistry has not been addressed in any detail. RESULTS: Taking advantage of gene silencing technology, we examined the specificity of several commercially available anti-phosphorylated GSK-3 antibodies. We show that antibodies raised to peptides containing the phosphorylated Ser21/9 epitope crossreact with unidentified antigens that are highly expressed by mitotic cells and that mainly localise to spindle poles. In addition, two antibodies raised to peptides containing the phosphorylated Tyr279/216 epitope recognise an unidentified protein at focal contacts, and a third antibody recognises a protein found in Ki-67-positive cell nuclei. While the phosphorylated Ser9/21 GSK-3 antibodies also recognise other proteins whose levels increase in mitotic cells in western blots, the phosphorylated Tyr279/216 antibodies appear to be specific in western blotting. However, we cannot rule out the posssibility that they recognise very large or very small proteins that might not be detected using a standard western blotting approach. CONCLUSIONS: Our findings indicate that care should be taken when examining the subcellular localisation of active or inactive GSK-3 and, furthermore, suggest that the role of GSK-3 phosphorylation in some cellular processes be reassessed. REVIEWERS: Dr. David Kaplan, Dr. Robert Murphy and Dr. Cara Gottardi (nominated by Dr Avinash Bhandoola.)
format Text
id pubmed-3039639
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-30396392011-02-16 Issues associated with the use of phosphospecific antibodies to localise active and inactive pools of GSK-3 in cells Campa, Victor M Kypta , Robert M Biol Direct Research ABSTRACT: BACKGROUND: Glycogen synthase kinase-3 (GSK-3) is a ubiquitously expressed serine/threonine (Ser/Thr) kinase comprising two isoforms, GSK-3α and GSK-3β. Both enzymes are similarly inactivated by serine phosphorylation (GSK-3α at Ser21 and GSK-3β at Ser9) and activated by tyrosine phosphorylation (GSK-3α at Tyr279 and GSK-3β at Tyr216). Antibodies raised to phosphopeptides containing the sequences around these phosphorylation sites are frequently used to provide an indication of the activation state of GSK-3 in cell and tissue extracts. These antibodies have further been used to determine the subcellular localisation of active and inactive forms of GSK-3, and the results of those studies support roles for GSK-3 phosphorylation in diverse cellular processes. However, the specificity of these antibodies in immunocytochemistry has not been addressed in any detail. RESULTS: Taking advantage of gene silencing technology, we examined the specificity of several commercially available anti-phosphorylated GSK-3 antibodies. We show that antibodies raised to peptides containing the phosphorylated Ser21/9 epitope crossreact with unidentified antigens that are highly expressed by mitotic cells and that mainly localise to spindle poles. In addition, two antibodies raised to peptides containing the phosphorylated Tyr279/216 epitope recognise an unidentified protein at focal contacts, and a third antibody recognises a protein found in Ki-67-positive cell nuclei. While the phosphorylated Ser9/21 GSK-3 antibodies also recognise other proteins whose levels increase in mitotic cells in western blots, the phosphorylated Tyr279/216 antibodies appear to be specific in western blotting. However, we cannot rule out the posssibility that they recognise very large or very small proteins that might not be detected using a standard western blotting approach. CONCLUSIONS: Our findings indicate that care should be taken when examining the subcellular localisation of active or inactive GSK-3 and, furthermore, suggest that the role of GSK-3 phosphorylation in some cellular processes be reassessed. REVIEWERS: Dr. David Kaplan, Dr. Robert Murphy and Dr. Cara Gottardi (nominated by Dr Avinash Bhandoola.) BioMed Central 2011-01-24 /pmc/articles/PMC3039639/ /pubmed/21261990 http://dx.doi.org/10.1186/1745-6150-6-4 Text en Copyright ©2011 Campa and Kypta ; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Campa, Victor M
Kypta , Robert M
Issues associated with the use of phosphospecific antibodies to localise active and inactive pools of GSK-3 in cells
title Issues associated with the use of phosphospecific antibodies to localise active and inactive pools of GSK-3 in cells
title_full Issues associated with the use of phosphospecific antibodies to localise active and inactive pools of GSK-3 in cells
title_fullStr Issues associated with the use of phosphospecific antibodies to localise active and inactive pools of GSK-3 in cells
title_full_unstemmed Issues associated with the use of phosphospecific antibodies to localise active and inactive pools of GSK-3 in cells
title_short Issues associated with the use of phosphospecific antibodies to localise active and inactive pools of GSK-3 in cells
title_sort issues associated with the use of phosphospecific antibodies to localise active and inactive pools of gsk-3 in cells
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3039639/
https://www.ncbi.nlm.nih.gov/pubmed/21261990
http://dx.doi.org/10.1186/1745-6150-6-4
work_keys_str_mv AT campavictorm issuesassociatedwiththeuseofphosphospecificantibodiestolocaliseactiveandinactivepoolsofgsk3incells
AT kyptarobertm issuesassociatedwiththeuseofphosphospecificantibodiestolocaliseactiveandinactivepoolsofgsk3incells